Overview

Study Examining PrEP-001 in Healthy Subjects

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.

Phase:

Phase 2

Details

Lead Sponsor:

Hvivo

Collaborator:

Prep Biopharm Limited